TY - JOUR
T1 - Hydrogel-Induced Cell Membrane Disruptions Enable Direct Cytosolic Delivery of Membrane-Impermeable Cargo
AU - Van Hoeck, Jelter
AU - Van de Vyver, Thijs
AU - Harizaj, Aranit
AU - Goetgeluk, Glenn
AU - Merckx, Pieterjan
AU - Liu, Jing
AU - Wels, Mike
AU - Sauvage, Félix
AU - De Keersmaecker, Herlinde
AU - Vanhove, Christian
AU - de Jong, Olivier G.
AU - Vader, Pieter
AU - Dewitte, Heleen
AU - Vandekerckhove, Bart
AU - Braeckmans, Kevin
AU - De Smedt, Stefaan C.
AU - Raemdonck, Koen
N1 - Funding Information:
J.V.H. and T.V.d.V. are doctoral fellows of the Research Foundation‐Flanders (Grants 1S62519N, 1198719N, FWO, Belgium). P.M. is a doctoral fellow of the FWO (grant 1S30616N) with financial support of the Flanders Innovation and Entrepreneurship Agency (VLAIO). J.L. gratefully acknowledges the financial support from the China Scholarship Council (CSC) (No. 201506750012) and the Ghent University Special Research Fund (No. 01SC1416). H.D. is a post‐doctoral fellow of the Ghent University Special Research Fund (BOF.PDO.2019.0018.01). K.R. acknowledges the FWO for a postdoctoral research grant (1507313N) and through funding of the ERA‐CVD JTC 2018 (ERA‐NET, AtheroInside). The authors would additionally like to acknowledge the funding by the Ghent University Special Research Fund (No. 01IO1214). Funding by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant No. 648124) is acknowledged with gratitude. The authors thank the Centre for Advanced Light Microscopy at Ghent University (Belgium) for the use and support of microscopy experiments.
Funding Information:
J.V.H. and T.V.d.V. are doctoral fellows of the Research Foundation-Flanders (Grants 1S62519N, 1198719N, FWO, Belgium). P.M. is a doctoral fellow of the FWO (grant 1S30616N) with financial support of the Flanders Innovation and Entrepreneurship Agency (VLAIO). J.L. gratefully acknowledges the financial support from the China Scholarship Council (CSC) (No. 201506750012) and the Ghent University Special Research Fund (No. 01SC1416). H.D. is a post-doctoral fellow of the Ghent University Special Research Fund (BOF.PDO.2019.0018.01). K.R. acknowledges the FWO for a postdoctoral research grant (1507313N) and through funding of the ERA-CVD JTC 2018 (ERA-NET, AtheroInside). The authors would additionally like to acknowledge the funding by the Ghent University Special Research Fund (No. 01IO1214). Funding by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (Grant No. 648124) is acknowledged with gratitude. The authors thank the Centre for Advanced Light Microscopy at Ghent University (Belgium) for the use and support of microscopy experiments.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
PY - 2021/7/28
Y1 - 2021/7/28
N2 - Intracellular delivery of membrane-impermeable cargo offers unique opportunities for biological research and the development of cell-based therapies. Despite the breadth of available intracellular delivery tools, existing protocols are often suboptimal and alternative approaches that merge delivery efficiency with both biocompatibility, as well as applicability, remain highly sought after. Here, a comprehensive platform is presented that exploits the unique property of cationic hydrogel nanoparticles to transiently disrupt the plasma membrane of cells, allowing direct cytosolic delivery of uncomplexed membrane-impermeable cargo. Using this platform, which is termed Hydrogel-enabled nanoPoration or HyPore, the delivery of fluorescein isothiocyanate (FITC)–dextran macromolecules in various cancer cell lines and primary bovine corneal epithelial cells is convincingly demonstrated. Of note, HyPore demonstrates efficient FITC-dextran delivery in primary human T cells, outperforming state-of-the-art electroporation-mediated delivery. Moreover, the HyPore platform enables cytosolic delivery of functional proteins, including a histone-binding nanobody as well as the enzymes granzyme A and Cre-recombinase. Finally, HyPore-mediated delivery of the MRI contrast agent gadobutrol in primary human T cells significantly improves their T1-weighted MRI signal intensities compared to electroporation. Taken together, HyPore is proposed as a straightforward, highly versatile, and cost-effective technique for high-throughput, ex vivo manipulation of primary cells and cell lines.
AB - Intracellular delivery of membrane-impermeable cargo offers unique opportunities for biological research and the development of cell-based therapies. Despite the breadth of available intracellular delivery tools, existing protocols are often suboptimal and alternative approaches that merge delivery efficiency with both biocompatibility, as well as applicability, remain highly sought after. Here, a comprehensive platform is presented that exploits the unique property of cationic hydrogel nanoparticles to transiently disrupt the plasma membrane of cells, allowing direct cytosolic delivery of uncomplexed membrane-impermeable cargo. Using this platform, which is termed Hydrogel-enabled nanoPoration or HyPore, the delivery of fluorescein isothiocyanate (FITC)–dextran macromolecules in various cancer cell lines and primary bovine corneal epithelial cells is convincingly demonstrated. Of note, HyPore demonstrates efficient FITC-dextran delivery in primary human T cells, outperforming state-of-the-art electroporation-mediated delivery. Moreover, the HyPore platform enables cytosolic delivery of functional proteins, including a histone-binding nanobody as well as the enzymes granzyme A and Cre-recombinase. Finally, HyPore-mediated delivery of the MRI contrast agent gadobutrol in primary human T cells significantly improves their T1-weighted MRI signal intensities compared to electroporation. Taken together, HyPore is proposed as a straightforward, highly versatile, and cost-effective technique for high-throughput, ex vivo manipulation of primary cells and cell lines.
KW - cell therapy
KW - contrast-enhanced MRI
KW - hydrogels
KW - intracellular delivery
KW - membrane disruption
KW - nanogels
KW - protein delivery
UR - http://www.scopus.com/inward/record.url?scp=85107325898&partnerID=8YFLogxK
U2 - 10.1002/adma.202008054
DO - 10.1002/adma.202008054
M3 - Article
AN - SCOPUS:85107325898
SN - 0935-9648
VL - 33
SP - 1
EP - 19
JO - Advanced materials
JF - Advanced materials
IS - 30
M1 - 2008054
ER -